Antibody-Positive Autoimmune Encephalitis and Paraneoplastic Neurological Syndrome: Epidemiology and Outcome of Neuronal Antibody Testing in Sweden

Table 2

Final diagnosis of patients not fulfilling diagnostic criteria of definite AE or definite PNS.

Diagnosis	Patients ()	Antibodies
Probable PNS^†	4	CV2, Amphiphysin, SOX1
Malignancy without PNS	4	Zic4, CASPR2, GAD65
Autoimmune CNS disease	5
Autoimmune encephalitis^‡	2	CASPR2, GAD65
IgLON5 encephalomyelitis	1	IgLON5
Autoimmune cerebellitis	2	GAD65
Stiff person syndrome	1	GAD65
CNS infection	5	CV2, Ma2/Ta, NMDAR, CASPR2, Yo
Demyelinating disorders of CNS	2	NMDAR, Zic4
Neuropathy	8
AIDP	3	SOX1, Hu, CV2
CIDP	2	GAD65, Zic4
Other	3	Yo, GABA-B, SOX1
Neurosarcoidosis	1	SOX1
Movement disorders	9
Cerebellar ataxia	4	SOX1, Ma2/Ta, Ri, NMDAR
Other	5	Amphiphysin, CASPR2, Yo, Zic4
Creutzfeldt Jakob’s disease	1	NMDAR
Psychiatric diagnosis	4	NMDAR, Zic4, Ma2/Ta
Diabetes type 1	5	GAD65
Other	14	GAD65, Yo, CASPR2, CV2, SOX1, Zic4, NMDAR

The final diagnosis, according to treating physician, of patients who did not meet criteria for definite AE, definite anti-NMDAR encephalitis, or definite PNS but tested positive for a neuronal antibody 2015–2019 in Healthcare region Mid Sweden. There is no certain association between all diagnoses and antibodies presented in this table. ^†Probable PNS according to PNS-Care Score, diagnosed as PNS by treating physicians. ^‡Diagnosed as autoimmune encephalitis by treating physician but does not fulfill diagnostic criteria. Abbreviations: AE: autoimmune encephalitis; PNS: paraneoplastic neurological syndrome; AIDP: acute inflammatory demyelinating polyneuropathy; CIDP: chronic inflammatory demyelinating polyneuropathy.